Affidea Piraeus Biopathological
Affidea Piraeus Biopathological is recorded as a service provider in 20 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 20 trials · Latest update first
A Phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of belimumab administered subcutaneously in adults with interstitial lung disease (ILD) associated with connective tissue disease (CTD).
Sponsor Glaxosmithkline Research & Development Limited
- Start (EU)
- Latest update
- Estimated end
Safety and efficacy of once-weekly subcutaneous and once-daily oral NNC0487-0111 in participants with type 2 diabetes – a dose finding study
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
Operational learnings available1 trial-level finding · Read insights
- The study was conducted in 11 countries: Bulgaria, Croatia, Germany, Greece, Hungary, Japan, Poland, Romania, Slovakia, Spain, and the United States of America.
These findings describe the trial, not the service provider’s performance or responsibility.
Efficacy and safety of NNC0487-0111 compared to placebo on morbidity and mortality in people with heart failure with preserved or mildly reduced ejection fraction and obesity (HF-POLARIS).
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Multicenter, Open-Label Study of Velzatinib (GSK6042981) versus Imatinib in Participants with Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST)
Sponsor Glaxosmithkline Research & Development Limited
- Start (EU)
- Latest update
- Estimated end
A Phase 2/3, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of belimumab administered subcutaneously in adults with systemic sclerosis associated interstitial lung disease (SSc-ILD)
Sponsor Glaxosmithkline Research & Development Limited
- Start (EU)
- Latest update
- Estimated end
Zenagamtide use for the reduction of risk of major adverse cardiovascular events in people with established atherosclerotic cardiovascular disease and either overweight or obesity (AMBIENCE)
Sponsor Novo Nordisk A/S
- Start (EU)
- Not reported
- Latest update
- Estimated end
A study comparing the effect and safety of once weekly dosing of somapacitan with daily Norditropin® as well as evaluating long-term safety of somapacitan in a basket study design in children with short stature either born small for gestational age or with Turner syndrome, Noonan syndrome, or idiopathic short stature
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
A clinical study to compare efficacy and safety of two different doses of CagriSema and semaglutide in participants with obesity with or without type 2 diabetes
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
Efficacy and safety of zenagamtide s.c. once weekly compared to insulin glargine s.c. once daily in participants with type 2 diabetes and increased cardiovascular risk inadequately controlled on 1–3 oral glucose-lowering medications (AMBITION 7)
Sponsor Novo Nordisk A/S
- Start (EU)
- Not reported
- Latest update
- Estimated end
ARTEMIS - Effects of ziltivekimab versus placebo on cardiovascular outcomes in patients with acute myocardial infarction.
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
An open-label, multi-centre, rollover study to characterise long-term safety and efficacy of etavopivat in adults, adolescents and children who have sickle cell disease or thalassaemia and have completed a treatment period in an etavopivat study
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
A global phase 3, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
Efficacy and safety of co-administered cagrilintide and semaglutide (CagriSema) 1.0 mg/1.0 mg s.c. once weekly versus tirzepatide 5 mg s.c. once weekly in participants with type 2 diabetes inadequately controlled on metformin, SGLT2 inhibitor or both
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
Weight Maintenance in Adolescents With Obesity; Long-Term Treatment With Semaglutide s.c. 2.4 mg Once-weekly
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
ZEUS - Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARLIMAB + DOCETAXEL TO DOSTARLIMAB + DOCETAXEL TO DOCETAXEL ALONE IN PARTICIPANTS WITH ADVANCED NONSMALL CELL LUNG CANCER WHO HAVE PROGRESSED ON PRIOR ANTI PD (L)1 THERAPY AND CHEMOTHERAPY (COSTAR LUNG)
Sponsor Glaxosmithkline Research & Development Limited
- Start (EU)
- Latest update
- Estimated end
An open-label study to investigate the long-term safety and efficacy of belimumab in adults with interstitial lung disease (ILD) associated with systemic sclerosis (SSc) and other connective tissue diseases (CTD)
Sponsor Glaxosmithkline Research & Development Limited
- Start (EU)
- Latest update
- Estimated end
Phase 3, Multicenter, Randomized, Open-label Clinical Study of GSK5764227, a B7-H3 Antibody Drug Conjugate (ADC), compared with Topotecan in Participants with Relapsed Small Cell Lung Cancer (SCLC)
Sponsor Glaxosmithkline Research & Development Limited
- Start (EU)
- Latest update
- Estimated end
Efficacy and safety of co-administered cagrilintide and semaglutide (CagriSema) s.c. in doses 2.4/2.4 mg and 1.0/1.0 mg once weekly versus semaglutide 2.4 mg and 1.0 mg, cagrilintide 2.4 mg and placebo in participants with type 2 diabetes inadequately controlled on metformin with or without an SGLT2 inhibitor
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
Effects of NNC0194-0499 alone and in combination with semaglutide, of semaglutide alone, and of cagrilintide alone and in combination with semaglutide on liver damage and alcohol use in people with alcohol-related liver disease
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Affidea Piraeus Biopathological?
The 2026-10-09 snapshot links Affidea Piraeus Biopathological to 20 distinct CTIS trials. Recorded services include Laboratory services, Cardiac services, Exams to be performed eye examination with fundus photography or by slit-lamp biomicroscopy examination using a pre-corneal or corneal contact lens. Optical coherence tomography (OCT), Ophthalmological examinations, among 11 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Affidea Piraeus Biopathological?
The most frequently recorded therapeutic areas are Metabolic Disorders, Endocrinology, Cardiology, Immunology. Recorded phases include Phase 3, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Affidea Piraeus Biopathological conducted?
The linked trials record locations in 24 countries, including Greece, Spain, Germany, Italy, France. These are trial locations, not confirmed office locations or countries where Affidea Piraeus Biopathological delivered services.
What can this page tell me about Affidea Piraeus Biopathological's trial experience?
Browse 20 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Affidea Piraeus Biopathological. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Affidea Piraeus Biopathological